Recro Pharma Names CCO

Recro Pharma Inc., a specialty pharma company developing non-opioid therapies for pain, has appointed Fred Graff chief commercial officer. Graff brings more than 20 years' experience to Recro and started his career at Rhone Poulenc Rorer where he held various roles including director of sales, US cardiovascular division. Previously he was senior vice president of sales at Sepracor Pharmaceuticals and later he was vice president of sales at Vanda Pharmaceuticals.

Recro Pharma Inc., a specialty pharma company developing non-opioid therapies for pain, has appointed Fred Graff chief commercial officer. Graff brings more than 20 years' experience to Recro and started his career at Rhone Poulenc Rorer where he held various roles including director of sales, US cardiovascular division. Previously he was senior vice president of sales at Sepracor Pharmaceuticals and later he was vice president of sales at Vanda Pharmaceuticals.

Welcome to Scrip

Create an account to read this article

More from Neurological

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

More from Therapy Areas

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.